SA520411406B1 - مركبات مثبطة لمستقبل حمض ليسوفوسفاتيديك 1 - Google Patents

مركبات مثبطة لمستقبل حمض ليسوفوسفاتيديك 1

Info

Publication number
SA520411406B1
SA520411406B1 SA520411406A SA520411406A SA520411406B1 SA 520411406 B1 SA520411406 B1 SA 520411406B1 SA 520411406 A SA520411406 A SA 520411406A SA 520411406 A SA520411406 A SA 520411406A SA 520411406 B1 SA520411406 B1 SA 520411406B1
Authority
SA
Saudi Arabia
Prior art keywords
acid receptor
inhibitor compounds
lysophosphatidic acid
lysophosphatidic
receptor
Prior art date
Application number
SA520411406A
Other languages
English (en)
Inventor
زهانج اكسيجون
ام ايه تينوى
وو لينج
Original Assignee
ايلاي ليلى اند كومباني
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ايلاي ليلى اند كومباني filed Critical ايلاي ليلى اند كومباني
Publication of SA520411406B1 publication Critical patent/SA520411406B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

يتعلق الاختراع الحالي بتوفير مركب له الصيغة (I) أو ملح صيدلي pharmaceutical salt منه، ويتم وصف استخدامه، وطرق تحضيره.
SA520411406A 2017-09-04 2020-02-25 مركبات مثبطة لمستقبل حمض ليسوفوسفاتيديك 1 SA520411406B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2017/100354 WO2019041340A1 (en) 2017-09-04 2017-09-04 LYSOPHOSPHATIDE ACID RECEPTOR 1 RECEPTOR INHIBITORS (LPAR1)
PCT/US2018/048249 WO2019046239A1 (en) 2017-09-04 2018-08-28 LYSOPHOSPHATIDE ACID RECEPTOR 1 RECEPTOR INHIBITORS (LPAR1)

Publications (1)

Publication Number Publication Date
SA520411406B1 true SA520411406B1 (ar) 2022-08-28

Family

ID=63528947

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520411406A SA520411406B1 (ar) 2017-09-04 2020-02-25 مركبات مثبطة لمستقبل حمض ليسوفوسفاتيديك 1

Country Status (13)

Country Link
US (2) US11365185B2 (ar)
EP (1) EP3679032B1 (ar)
JP (1) JP6854386B2 (ar)
KR (1) KR102341064B1 (ar)
CN (1) CN111032647B (ar)
AU (1) AU2018323969B2 (ar)
BR (1) BR112020002217A2 (ar)
CA (1) CA3073983C (ar)
EA (1) EA039482B1 (ar)
IL (1) IL273000B2 (ar)
MX (1) MX2020002430A (ar)
SA (1) SA520411406B1 (ar)
WO (2) WO2019041340A1 (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220101137A (ko) 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN113461640B (zh) * 2021-06-17 2023-08-11 中央民族大学 Lpar1抑制剂、医药用途及其制备方法
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
BR112013014019A2 (pt) * 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
WO2012138797A1 (en) * 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US9526091B2 (en) * 2012-03-16 2016-12-20 Intel Corporation Method and apparatus for coordination of self-optimization functions in a wireless network
MX2018006225A (es) * 2015-11-20 2018-11-09 Ube Industries Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).

Also Published As

Publication number Publication date
EP3679032A1 (en) 2020-07-15
MX2020002430A (es) 2020-07-13
KR102341064B1 (ko) 2021-12-20
IL273000A (en) 2020-04-30
CN111032647B (zh) 2023-05-02
CA3073983C (en) 2023-10-17
US20220281845A1 (en) 2022-09-08
EA202090368A1 (ru) 2020-06-09
AU2018323969A1 (en) 2020-02-20
EA039482B1 (ru) 2022-02-01
US11365185B2 (en) 2022-06-21
AU2018323969B2 (en) 2020-07-16
KR20200035440A (ko) 2020-04-03
CA3073983A1 (en) 2019-03-07
CN111032647A (zh) 2020-04-17
EP3679032B1 (en) 2023-10-04
US20200231568A1 (en) 2020-07-23
JP2020532550A (ja) 2020-11-12
JP6854386B2 (ja) 2021-04-07
IL273000B1 (en) 2023-04-01
BR112020002217A2 (pt) 2020-07-28
WO2019041340A1 (en) 2019-03-07
WO2019046239A1 (en) 2019-03-07
IL273000B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
SA520411406B1 (ar) مركبات مثبطة لمستقبل حمض ليسوفوسفاتيديك 1
PH12020500673A1 (en) Compounds
PH12018501099A1 (en) Novel biphenyl compound or salt thereof
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
PH12017501523A1 (en) Selective bace1 inhibitors
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2015011913A (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
PH12016501517B1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
PH12018500282A1 (en) Cgrp receptor antagonists
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors
AU2016330503A8 (en) Therapeutic compounds and methods of use thereof
MY189798A (en) Novel biphenyl compound or salt thereof
TH168843A (th) กระบวนการเตรียมสารยับยั้ง jak1 และรูปแบบใหม่ของสารยับยั้งดังกล่าว